Ramin Mohammadzadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ramin Mohammadzadeh has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Bahman Yousefi
Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Behzad Baradaran
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications Hadi Valizadeh
2 shared publications- Nejla Ahmadiyan
Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications Parvin Zakeri-Milani
2 shared publicationsAhmadiyan Nejla
1 shared publication
Latest Publications
- 4 July 2024
- Published by Wiley in Phytotherapy Research
- Vol. 38 (8) , 4240-4260
Curcumin and nano‐curcumin applications in psychiatric disorders
Psychiatric disorders cause long‐lasting disabilities across different age groups. While various medications are available for mental disorders, some patients do not fully benefit from them or experience treatment resistance. The pathogenesis of psychiatric disorders involves multiple mechanisms, including an increase in the inflammatory response. Targeting inflammatory mechanisms has shown promise as a therapeutic approach for these disorders. Curcumin, known for its anti‐inflammatory properties and potential neuroprotective effects, has been the subject of studies investigating its potential as a treatment option for psychiatric disorders. This review comprehensively examines the potential therapeutic role of curcumin and its nanoformulations in psychiatric conditions, including major depressive disorder (MDD), bipolar disorder, schizophrenia, and anxiety disorders. There is lack of robust clinical trials across all the studied psychiatric disorders, particularly bipolar disorder and schizophrenia. More studies have focused on MDD. Studies on depression indicate that curcumin may be effective as an antidepressant agent, either alone or as an adjunct therapy. However, inconsistencies exist among study findings, highlighting the need for further research with improved blinding, optimized dosages, and treatment durations. Limited evidence supports the use of curcumin for bipolar disorder, making its therapeutic application challenging. Well‐designed clinical trials are warranted to explore its potential therapeutic benefits. Exploring various formulations and delivery strategies, such as utilizing liposomes and nanoparticles, presents intriguing avenues for future research. More extensive clinical trials are needed to assess the efficacy of curcumin as a standalone or adjunctive treatment for psychiatric disorders, focusing on optimal dosages, formulations, and treatment durations.
- 4 July 2024
- Published by Wiley in Phytotherapy Research
- Vol. 38 (8) , 4240-4260
Curcumin and nano‐curcumin applications in psychiatric disorders
Psychiatric disorders cause long‐lasting disabilities across different age groups. While various medications are available for mental disorders, some patients do not fully benefit from them or experience treatment resistance. The pathogenesis of psychiatric disorders involves multiple mechanisms, including an increase in the inflammatory response. Targeting inflammatory mechanisms has shown promise as a therapeutic approach for these disorders. Curcumin, known for its anti‐inflammatory properties and potential neuroprotective effects, has been the subject of studies investigating its potential as a treatment option for psychiatric disorders. This review comprehensively examines the potential therapeutic role of curcumin and its nanoformulations in psychiatric conditions, including major depressive disorder (MDD), bipolar disorder, schizophrenia, and anxiety disorders. There is lack of robust clinical trials across all the studied psychiatric disorders, particularly bipolar disorder and schizophrenia. More studies have focused on MDD. Studies on depression indicate that curcumin may be effective as an antidepressant agent, either alone or as an adjunct therapy. However, inconsistencies exist among study findings, highlighting the need for further research with improved blinding, optimized dosages, and treatment durations. Limited evidence supports the use of curcumin for bipolar disorder, making its therapeutic application challenging. Well‐designed clinical trials are warranted to explore its potential therapeutic benefits. Exploring various formulations and delivery strategies, such as utilizing liposomes and nanoparticles, presents intriguing avenues for future research. More extensive clinical trials are needed to assess the efficacy of curcumin as a standalone or adjunctive treatment for psychiatric disorders, focusing on optimal dosages, formulations, and treatment durations.
- Open Access
- 13 November 2021
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 17 (2)
Efficacy and Safety of Novel Herbal Tablets in COVID-19 Patients in Hospital Stay Days, ICU Admission and Mortality Rate Thereof: An Ppen-Label, Single-Blind Randomized Clinical Trial
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the super-spreading virus, has claimed hundreds of thousands of lives worldwide. Objectives: This study aimed to evaluate the effectiveness of the novel suggested herbal compound, formulated as compressed tablets, in reducing the length of hospital stay (LoS), intensive care unit (ICU) admission, and mortality in confirmed COVID-19 cases. Methods: Following an open-label, single-blind randomized clinical trial design, a total of 200 patients aged 18-65 admitted to Imam Reza hospital in Tabriz, northwest of Iran, were randomized to intervention and control groups in a 1:1 ratio, i.e., 100 subjects in each group. The former received standard treatment along with the compressed herbal tablets, and the latter only received the standard treatment. Adverse reactions incidence within 180 days after the beginning of the intervention was set as the primary safety endpoint. The most important and active ingredients of the tablets were Terminalia chebula, Glycyrrhiza glabra, Anacyclus pyrethrum, Senna alexandrina, Ferrula asafoetida, Pistacia lentiscus, Zizyphus jujuba, Crocus sativus, Echinacea angustifolia, and Hyssopus officinalis. This trial is registered at the Iranian Registry of Clinical Trials (code: IRCT20200522047545N1). Results: Those in the intervention arm had significantly lower rates of LoS (7.38 vs. 9.45, P = 0.030), ICU admission (6 out of 100 vs. 32 out of 100, P = 0.000), and mortality (1 vs. 19 out of 100, P = 0.000). Conclusions: Our observations suggest that adequate improvement is provided by the prepared herbal compound along with substantial savings in hospitalization hoteling costs. While further multi-center studies with a larger sample size are needed to extend our knowledge regarding the effect of this new option, these novel clinical data may well provide a new alternative for the management of COVID-19 disease.
- 13 November 2021
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 17 (2)
Open AccessEfficacy and Safety of Novel Herbal Tablets in COVID-19 Patients in Hospital Stay Days, ICU Admission and Mortality Rate Thereof: An Ppen-Label, Single-Blind Randomized Clinical Trial
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the super-spreading virus, has claimed hundreds of thousands of lives worldwide. Objectives: This study aimed to evaluate the effectiveness of the novel suggested herbal compound, formulated as compressed tablets, in reducing the length of hospital stay (LoS), intensive care unit (ICU) admission, and mortality in confirmed COVID-19 cases. Methods: Following an open-label, single-blind randomized clinical trial design, a total of 200 patients aged 18-65 admitted to Imam Reza hospital in Tabriz, northwest of Iran, were randomized to intervention and control groups in a 1:1 ratio, i.e., 100 subjects in each group. The former received standard treatment along with the compressed herbal tablets, and the latter only received the standard treatment. Adverse reactions incidence within 180 days after the beginning of the intervention was set as the primary safety endpoint. The most important and active ingredients of the tablets were Terminalia chebula, Glycyrrhiza glabra, Anacyclus pyrethrum, Senna alexandrina, Ferrula asafoetida, Pistacia lentiscus, Zizyphus jujuba, Crocus sativus, Echinacea angustifolia, and Hyssopus officinalis. This trial is registered at the Iranian Registry of Clinical Trials (code: IRCT20200522047545N1). Results: Those in the intervention arm had significantly lower rates of LoS (7.38 vs. 9.45, P = 0.030), ICU admission (6 out of 100 vs. 32 out of 100, P = 0.000), and mortality (1 vs. 19 out of 100, P = 0.000). Conclusions: Our observations suggest that adequate improvement is provided by the prepared herbal compound along with substantial savings in hospitalization hoteling costs. While further multi-center studies with a larger sample size are needed to extend our knowledge regarding the effect of this new option, these novel clinical data may well provide a new alternative for the management of COVID-19 disease.
- 1 October 2020
- Published by Elsevier in Life Sciences
- Vol. 259, 118255
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem
- 1 October 2020
- Published by Elsevier in Life Sciences
- Vol. 259, 118255
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem
- 15 July 2019
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 23 (4) , 632-641
Attenuation of Intestinal Efflux Pump thru Polymers and Preservatives
- 15 July 2019
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 23 (4) , 632-641
Attenuation of Intestinal Efflux Pump thru Polymers and Preservatives
- Open Access
- 13 November 2018
- Published by Negah Scientific Publisher in Pharmaceutical and Biomedical Research
An overview on oral drug delivery via nano-based formulations
Oral drug administration is used for a large number of medications, intended to create a systemic effect in the body. Over the recent years, an increasing attention has been directed by pharmacists toward the development of successful formulations for oral drug delivery. However, this issue is still controversial in pharmaceutical technology with many limitations due to the numerous barriers against the absorption and permeability in the gastrointestinal tract. On the other hand, drug carriers play an important role in providing prolonged release and delivery and overcome the multiple barriers of maintaining appropriate bioavailability. Nano scaling of the particles, carriers, and polymers has also provided the capability to characterize and control materials in order to produce unique pharmaceutical components and structures. Furthermore, personalized healthcare, rational drug design, and site-specific targeted drug delivery are some of the profits gained from a nano-based formulation approach. This review aimed to evaluate the evidence on some different types of nanoscaled drug delivery systems, which allow for the delivery of smallmolecule drugs and facilitate the merging of larger particles, such as nucleic acids, peptides, and proteins. The delivery of these molecules to the exact target areas inside the body can be accomplished, which would decrease systemic adverse effects and allow for more effective application of the pharmaceutical preparations.
- 13 November 2018
- Published by Negah Scientific Publisher in Pharmaceutical and Biomedical Research
Open AccessAn overview on oral drug delivery via nano-based formulations
Oral drug administration is used for a large number of medications, intended to create a systemic effect in the body. Over the recent years, an increasing attention has been directed by pharmacists toward the development of successful formulations for oral drug delivery. However, this issue is still controversial in pharmaceutical technology with many limitations due to the numerous barriers against the absorption and permeability in the gastrointestinal tract. On the other hand, drug carriers play an important role in providing prolonged release and delivery and overcome the multiple barriers of maintaining appropriate bioavailability. Nano scaling of the particles, carriers, and polymers has also provided the capability to characterize and control materials in order to produce unique pharmaceutical components and structures. Furthermore, personalized healthcare, rational drug design, and site-specific targeted drug delivery are some of the profits gained from a nano-based formulation approach. This review aimed to evaluate the evidence on some different types of nanoscaled drug delivery systems, which allow for the delivery of smallmolecule drugs and facilitate the merging of larger particles, such as nucleic acids, peptides, and proteins. The delivery of these molecules to the exact target areas inside the body can be accomplished, which would decrease systemic adverse effects and allow for more effective application of the pharmaceutical preparations.
- 1 November 2016
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 42 (6) , 401-402
Novel Agents for Antimicrobial Solutions
- 1 November 2016
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 42 (6) , 401-402
Novel Agents for Antimicrobial Solutions
- Open Access
- 27 July 2015
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 8 (8) , e19766
Epidemiology of HIV/AIDS in the East Azerbaijan Province, Northwest of Iran
Background: This study was performed in response to the rapid propagation of HIV/AIDS across Iran and its status in this region. Accordingly, an evidence-based program is required to combat this disease. Objectives: The present study estimated the prevalence of HIV/AIDS in East Azerbaijan (population: 3,724,000). Materials and Methods: We created a database of all positive cases from 1987 to 2012. We also analyzed and described the epidemiological status of HIV/AIDS during a 25-year period by using SPSS. Results: In East Azerbaijan, 371 HIV/AIDS cases have been reported, i.e. 1 case per 10,000 population. The vast majority of reported cases (91%, n =338) were men, whereas only 9% (n = 33) were women. The mean age of patients was 30.8 ± 12.3 years. Unsafe drug injection (59%, n = 219) and sexual interaction (13%, n = 48) were the two major modes of HIV transmission. In addition, 7% (n = 25) of patients have been diagnosed with HIV, hepatitis B Virus, and hepatitis C virus simultaneously. Moreover, 60% (n = 205) of men were infected via drug injection, while 82% (n = 27) of women were infected via unprotected sexual interaction (P < 0.001). Conclusions: The results indicate a rapid increase in the number of HIV/AIDS cases in East Azerbaijan, necessitating immediate attention and strategies to combat the rapid spread of the disease. Development of provincial and national HIV/AIDS strategies demands more accurate and comprehensive HIV/AIDS surveillance. Keywords: HIV; Acquired Immunodeficiency Syndrome; Epidemiology
- 27 July 2015
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 8 (8) , e19766
Open AccessEpidemiology of HIV/AIDS in the East Azerbaijan Province, Northwest of Iran
Background: This study was performed in response to the rapid propagation of HIV/AIDS across Iran and its status in this region. Accordingly, an evidence-based program is required to combat this disease. Objectives: The present study estimated the prevalence of HIV/AIDS in East Azerbaijan (population: 3,724,000). Materials and Methods: We created a database of all positive cases from 1987 to 2012. We also analyzed and described the epidemiological status of HIV/AIDS during a 25-year period by using SPSS. Results: In East Azerbaijan, 371 HIV/AIDS cases have been reported, i.e. 1 case per 10,000 population. The vast majority of reported cases (91%, n =338) were men, whereas only 9% (n = 33) were women. The mean age of patients was 30.8 ± 12.3 years. Unsafe drug injection (59%, n = 219) and sexual interaction (13%, n = 48) were the two major modes of HIV transmission. In addition, 7% (n = 25) of patients have been diagnosed with HIV, hepatitis B Virus, and hepatitis C virus simultaneously. Moreover, 60% (n = 205) of men were infected via drug injection, while 82% (n = 27) of women were infected via unprotected sexual interaction (P < 0.001). Conclusions: The results indicate a rapid increase in the number of HIV/AIDS cases in East Azerbaijan, necessitating immediate attention and strategies to combat the rapid spread of the disease. Development of provincial and national HIV/AIDS strategies demands more accurate and comprehensive HIV/AIDS surveillance. Keywords: HIV; Acquired Immunodeficiency Syndrome; Epidemiology
- Open Access
- 7 February 2014
- Vol. 4 (3) , 219-224
Reduced ABCB1 Expression and Activity in the Presence of Acrylic Copolymers
Purpose: P-glycoprotein (P-gp; ABCB1), an integral membrane protein in the apical surface of human intestinal epithelial cells, plays a crucial role in the intestinal transport and efflux leading to changes in the bioavailability of oral pharmaceutical compounds. This study was set to examine the potential effects of three Eudragits RL100, S100 and L100 on the intestinal epithelial membrane transport of rhodammine-123 (Rho-123), a substrate of P-gp using a monolayer of human colon cancer cell line (Caco-2).
- 7 February 2014
- Vol. 4 (3) , 219-224
Open AccessReduced ABCB1 Expression and Activity in the Presence of Acrylic Copolymers
Purpose: P-glycoprotein (P-gp; ABCB1), an integral membrane protein in the apical surface of human intestinal epithelial cells, plays a crucial role in the intestinal transport and efflux leading to changes in the bioavailability of oral pharmaceutical compounds. This study was set to examine the potential effects of three Eudragits RL100, S100 and L100 on the intestinal epithelial membrane transport of rhodammine-123 (Rho-123), a substrate of P-gp using a monolayer of human colon cancer cell line (Caco-2).
- 5 December 2013
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 126 (23) , 4535
Novel agent for Helicobacter pylori infection management
- 5 December 2013
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 126 (23) , 4535
Novel agent for Helicobacter pylori infection management
- 1 December 2013
- Vol. 126 (23) , 4535
Novel agent for Helicobacter pylori infection management.